Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

To evaluate whether exenatide administered before breakfast and dinner (BD) or before lunch and dinner (LD) provided similar glycemic control in Latin American patients with type 2 diabetes mellitus (T2DM) who consume a small breakfast.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

In this open-label, 2-arm study, patients taking metformin, sulfonylureas, and/or thiazolidinediones were randomized to exenatide before BD or before LD (5-mug exenatide for 4 weeks, then 10-microg exenatide for 8 weeks).

Treatment assignment was determined by a computer-generated random sequence using an interactive response system.

How the Study Was Run

The design is described as randomized and open-label.

The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Everyone knew when Exenatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The methods mention a period of 4 weeks.

The primary endpoint was HbA(1c) change from baseline to endpoint.

Secondary endpoints included fasting serum glucose (FSG) level, 7-point SMBG profile, and safety.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Eating, Exenatide, Glucagon-Like Peptide 1, Glycated Hemoglobin and Hispanic or Latino.

What This Means in Plain Language

The paper is a randomized and open-label study of Exenatide over 4 weeks.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Current medical research and opinion), a journal based in England.

More context: the Exenatide compound page, all human trials.